BBIOBridgeBio Pharma, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 12282
Ticker: BBIO
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2019-06-27
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: BBIO

Detail

Enriched 2026-08-14 20:47

Market cap: $16,389,669,820.16
Shares outstanding (class): 195,486,278
Shares outstanding (weighted): 195,487,474
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 839
Location: PALO ALTO, CA
Homepage: https://www.bridgebio.com
Description: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Market cap and share counts drift.

Funds holding this security

246 funds · 254 positions · $3.21B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$412.72M	0.02%	5,557,828 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$298.74M	0.18%	4,022,939 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$287.94M	0.40%	3,877,396 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$167.17M	0.43%	2,251,189 NS	FIGI
Janus Henderson Enterprise Fund JANUS INVESTMENT FUND	—	$141.81M	0.69%	1,909,659 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$140.59M	0.17%	1,893,232 NS	FIGI
Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND	—	$115.19M	2.22%	1,551,141 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$96.10M	0.79%	1,294,072 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$91.98M	1.13%	1,238,687 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$88.13M	1.19%	1,186,816 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$67.33M	0.82%	906,623 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$64.17M	0.59%	864,149 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$63.16M	0.49%	850,480 NS	FIGI
Janus Henderson Triton Fund JANUS INVESTMENT FUND	—	$59.49M	1.15%	801,169 NS	FIGI
Hood River Small-Cap Growth Fund Manager Directed Portfolios	—	$50.82M	0.98%	684,355 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERBBIO
FIGI_COMPOSITEBBG00P9KDZK6
FIGI_SHARE_CLASSBBG00P9KDZL5
CIK0001743881
ISINUS10806X1028
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: BridgeBio Pharma is a biopharmaceutical company developing therapies, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.